# 2 Oxo benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives.

## Abstract
Compounds having the formula The compounds of the invention can be prepared by a number of chemical techniques.

## Claims
We claim 1. A compound of the formula EMI44.1 wherein RaÚ is hydroxy, halogen, nitro, amino, C3 to C8 cycloalkyl, aryl or aryloxy which may be substituted with halogen, Rê is hydrogen, halogen or lower alkyl, R3 is carboxy or a protected carboxy group, is sulfur, oxygen or methylene and A As lower alkylene, provided that when R2 is hydrogen and is sulfur or oxygen, Ra is not halogen, and pharmaceutically acce ptable salts thereof. 2. A compound of claim 1, wherein Ra1 is hydroxy, halogen, nitro, amino, C3 to C8 cycloalkyl, phenyl or phenoxy which may be substituted with a halogen and R3 is carboxy or lower alkoxycarbonyl. 3. A compound of claim 2, wherein R1 is halogen, phenyl or phenoxy, is halogen or lower alkyl, R3 is carboxy and is is sulfur or oxygen. 4. A compound of claim 3, wherein is sulfur. 5. A compound of claim 4, which is selected from the groups consisting of 2 oxo 5,6 dichloro 3 benzothiazolineacetic acid, 2 oxo 5 chloro 6 bromo 3 benzothiazolineacetic acid, 2 oxo 5 chloro 6 phenyl 3 benzothiazolineacetic acidt 2 oxo 5 methyl 6 phenyl 3 benzothiazolineacetic acids 2 oxo 5 chloro 6 phenoxy 3 benzothiazolineacetic acid, and pharmaceutically acceptable salt thereof. 6. A compound of claim 3, wherein a is oxygen. 7. A compound of claim 6, which is 2 oxo5 chloro 6 phenyl 3 benzoxazolineacetic acid and pharmaceutically acceptable salt thereof. 8. A process for preparing a compound of the formula EMI46.1 wherein Ra is hydroxy, halogen, nitro, amino, C3 to C8 cycloalkyl, aryl or aryloxy which may be substituted with halogen, R2 is hydrogen, halogen or lower alkyl, R3 is carboxy or a protected carboxy group, continued to the next page is sulfur, oxygen or methylene and A is lower alkylene, provided that when R2 is hydrogen and is is sulfur or oxygen, R1 is not halogen, a and pharmaceutically acceptable salts thereof, which comprises, a reacting a compound of the formula EMI47.1 wherein RaÚ, R2 and a are each as defined above, or i ts salt with a compound of the formula XÚ A R wherein R3 and A are each as defined above, andXÚ is an acid residue, or its salt to give a compound of the formula EMI47.2 wherein RaÚ, R2, R3, Y and A are each as defined above, or its salt .b reducing a compound of the formula EMI47.3 wherein R2, R , Ya and A are each as defined above, or its salt to give a compound of the formula EMI48.1 wherein R2, R3, Ya and A are each as defined above, or its Salt c reacting a compound of the formula EMI48.2 wherein Rê, R , Ya and A are each as defined above, or its salt with a diazotizing agent and then reacting the resultant compound with benzene, to give a compound of the formula EMI48.3 wherein R2, R3, a and A are each as defined above, or its salt d reacting a compound of the formula EMI48.4 wherein Rê, R , Ya and A are each as defined above, or its salt with a halogenating agent, to give a compound of the formula EMI49.1 wherein R2, R3, Y and A are each as defined above, and RbÚ is halogen or its salt e removing the carboxy protective group of a compound of the formula EMI49.2 wherein RaÚ, R2 Y and A are each as defined above, and Ra is a protected carboxy group, or its salt to give a compound of the formula EMI49.3 wherein R1 Rê Y and A are each as defined above a , Ia or its salt or f eliminating the lower alkyl moiety at the lower alkoxy group of the formula EMI49.4 wherein R2, X3, a and A are each as defined above, and R1 is lower alkoxy, or its salt to give a compound of the formula EMI50.1 wherein R2, R3, ra and A are each as defined above, or its salt. 9. A pharmaceutical composition which comprises, as an effective ingredient, at least one compound of the formula EMI50.2 wherein R1a is hydroxy, halogen, nitro, amino, C3 to C8 cycloalkyl, aryl or aryloxy which may be substituted with halogen, R2 is hydrogen, halogen or lower alkyl, R3 is carboxy or a protected carboxy group, is sulfur, oxygen or methylene and A is lower alkylene, provided that when R2 is hydrogen and is is sulfur or oxygen, Ra is not halogen, or pharmaceutically acceptable salts thereof with a pharmaceutically acceptable carrier. 10. A pharmaceutical composition which comprises, as an effective ingredient, at least one compound of the formula EMI51.1 wherein R1 is hydrogen, hydroxy, nitro, amino, lower alkoxy, halogen, C3 to C8 cycloalkyl, aryl, aryloxy which may be substituted with halogen, R2 is hydrogen, halogen or lower alkyl, R3 is carboxy or a protected carboxy group, Y is sulfur, oxygen, carbonyl or methylene and A is lower alkylene, or pharmaceutically acceptable salts thereof with a pharmaceutically acceptable carrier.

## Description
Lower Alkanoic Acid Derivatives, their Prenaration andPharmacentical Compositions comprisine the same Tais invention relates to a new pharmaceutical composition comprising certain lower alkancic acid derivatives. More particularly, it relates to a new pharmaceutical onmposition for the prevention and treatment of vailous diabetic complications comprising the lower alkanoic acid derivatives as an active ingredient, and to new compounds among the lower alkanoic acid derivatives and to processes for their preparation. This invention based on the discovery by the present inventors that certain lower alkanoic acid derivatives are highly potent inhibitors of aldose reductase and therefore useful fos the prevention and treatment of various diabetic complications Ce.g. cataracts, neuropathy, retinopathy and nephropathy . In this respect, it has been already known that spiro hydantoin compounds and S,6 dihydro 4H pyrrolo 3,2,1 ijlquinolin 1,2 dione are aldose reductase inhibitors cf. United States Patent Nos. 4,117,230 C1978 and 4,151,282 1979 . However, the aldose reductase inhibitors of this invention are structurally different from those prior compounds. Accordingly, one object of this invention is to provide a pharmaceutical composition for preventing and treating diabetic complications comprising, as an active ingredient, at least one of the lower alkanoic acid derivatives. Another object of this invention is to provide new lower alkanoic acid derivatives. Further object of this invention is to provide processes for the preparation of new lower alkanoic acid derivatives. The lower alkanoic acid derivatives can be represented by the formula EMI2.1 wherein R1 is hydrogen, hydroxy, nitro, amino, lower alkoxy, halogen, CC3 to C8 cycloalkyl, aryl or aryloxy which may be substituted with halogen, is is hydrogen, halogen or lower alkyl, R is carboxy or a protected carboxy group, Y is sulfur, oxygen, carbonyl or methylene and A is lower alkylene, and pharmaceutically acceptable salts thereof. Among the compounds represented by the above formula I , preferred new compounds of this invention can be represented by the formula EMI3.1 wherein RaÚ is hydroxy, halogen, nitro, amino, C3 to C8 cycloalkyl, aryl or aryloxy which may be substituted with halogen, is is sulfur, oxygen or methylene, R2, A and R3 are each defined above, provided that when Rê is hydrogen and Ya is sulfur or oxygen, R is not halogen, and pharmaceutically acceptable salts thereof. The new object compound Ia can be prepared by the following Precesses.Process 1EMI4.1 Process 2EMI4.2 Process 3EMI5.1 Process 4EMI5.2 Process 5EMI5.3 Process 6EMI5.4 wherein RaÚ, Rê, R , Ya and A are each as defined above, RbÚ is halogen, RcÚ is lower alkoxy, Ra is a protected carboxy and XÚ is an acid residue. Among the starting compound II , novel compound can be prepared by the following Preparations A , B and C and the others can be prepared by the similar manner thereto.Preparation A EMI6.1 EMI7.1 wherein RÚa, Rê and Ya are each as defined above,RÚd is hydroxy, halogen, nitro, C3 to C8 cycloalkyl, aryl or aryloxy which may be substituted with halogen,R4 is hydrogen or acyl, and x2 and X3 are each halogen. In the above and subsequent description of the present specification, suitable examples for various.definitions to be included within the scope of the invention are explained in details as follows. The te lower means 1 to 6 carbon atom s , unless otherwise indicated. Suitable lower alkoxy1 may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, hexyloxy and the like. Suitable halogen may include fluorine, chlorine, bromine or iodine. Suitable lower alkyl may include methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl and the like. Suitable protected carboxy group may include an esterified carboxy group such as lower alkoxycarbonyl e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc. and the like. Suitable lower alkylene 1 may include methylene, ethylene, ethylidene, trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene and the like. Suitable acid residue may include halogen as exemplified above, azido, acyloxy e.g. benzenesulfonyloxy, tosyloxy, etc. and the like. Suitable C3 to C8 cycloalkyln may include Cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Suitable naryl and aryl moiety in the term aryloxy which may be substituted with halogen may include, phenyl, tolyl, xylyl, napthyl and the like. Suitable acyl may include aliphatic acyl group and acyl group containing an aromatic or heterocyclic ring. And, suitable examples of the said acyl may be lower alkanoyl Ce.g. formyl, acetyl, etc. , lower alkoxycarbonyl e.g. methoxycarbonyl, ethoxycarbonyl, tert butoxycaronyl, etc. , lower alkanesulfonyl e.g. mesyl, ethanesulfonyl, etc. , arenesulfonyl Ce.g.benzensulfonyl, tosyl, etc. , aroyl e.g. benzoyl, toluoyl, etc. , phenyl lower alknnoyl e.g. phenylacetyl, phenylpropionyl, etc. , phenoxy lower alkanoyl Ce.g. phenoxyacetyl, etc. , and the like. The pharmaceutically acceptable salts of the compound I and CIa may include an inorganic or organic base salt such as a metal salt Ce.g. sodium salt, potassium salt, magnesium salt, calcium salt, etc. , ammonium salt, an amine salt e.g. ethanolamine salt, trimethylamine salt, triethylamine salt, dicyclohexylamine salt, etc. , an amino acid salt e.g.arginine salt, etc. and an inorganic or organic acid salt e.g. hydrochloride, sulfate, etc. . The processes for the preparation of the preferred new object compound Ia of this invention are explained in details as follows.Process 1 The object compound CIa or i s salt can be prepared by reacting the compound CII 3 or its salt with the compound III or its salt. Suitable salt of the compound II may include a metal salt and an acid salt as exemplified for the compound Ia . Suitable salt of the compound III may include an inorganic or organic base salt as exemplified for the compound Ia , This reaction is. usually carried out in a conven tional solvent such as acetone, chloroform, benzene, tetrahydrofuran, dimethylsulfoxide, N ,N dimethylformamide or any other solvent which does not adversely influence the reaction. This reaction is preferably carried out in the presence of an inorganic or organic base. The suitable base may include an inorganic or organic base such as alkali metal hydroxide e.g.sodium hydroxide, potassium hy.i.roxide, etc. , an alkaline earth metal hydroxideCe.g. magnesium hydroxide, calcium hydroxide, etc. , and alkali metal carbonate e.g. sodium carbonate, etc. , an alkaline earth metal carbonate e.g. magnesium carbonate, calcium carbonate, etc. , an alkali metal bicarbonate e.g. sodium bicarbonate, potassium bicarbonate, etc. , a trialkylamine e.g. trimethylamine, triethylamine, etc. , pyridine, picoline, a diazabicyclo compound 1,5 diazabicyclo 4,3,0 nonene 5, 1,5 diazabicyclo 5,4,0 undecene 5, 1,4 diazabicyclo t2,2,Z octane, etc. , an alkali metal acetate e.g.sodium acetate, potassium acetate, etc. , an alkali metal lower alkoxide e.g. sodium methoxide, sodium ethoxide, potassium t butoxide, etc. and the like. This reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating.Process 2 The compound 1êa or its salt can be prepared by reducing the compound Ia or its salt. Suitable salt of the compound tri may include an inorganic or organic base salt as exemplified for the compound Ia . This reduction is carried out by a conventional method such as a method of using a combination of metal e.g. iron, tin, etc. and acid e.g. hydrochloric acid, etc. , a catalytic reduction using a conventional catalyst e.g. Raney nickel, platinum on carbon, palladium on carbon, etc. and the like. This reduction is usually carried out in a conventional solvent such as water, methanol, ethanol, tetrahydro furan, ethyl, acetate, acetic acid or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating. Process 3 The compound 1 a or its salt can be prepared by reacting the compound 1êa or its salt with a diazotizing agent and then reacting the resultant compound with benzene. Suitable salt of the compound 1êa may include the ones as exemplified for the compound Ia . Suitable examples of the diazotizing agent may include a lower alkyl nitrite Ce.g. methyl nitrite, ethyl nitrite, propyl nitrite, butyl nitrite, t butyl nitrite, etc. an alkali metal nitrite Ce.g. sodium nitrite, etc. and the like. This diazotization reaction is usually carried out in a solvent such as water or any other solvent which does not adversely influence the reaction. This diazotization can be preferably carried out in the presence of a mineral acid such as hydrochloric acid, sulfuric acid, and the like. This reaction temperature is not critical and the reaction is usually carried out under cooling or at ambient temperature. Thus obtained reaction mixture can be used in the subsequent reaction. The subsequent reaction using benzene is usually carried out in the presence of an inorganic or organic base such as alkali oralkaline earth metal hydroxide Ce.g. sodium hydroxide, etc. , alkali metal acetate e.g. sodium acetate, etc. and the like. This reaction temperature is not critical and the reaction is usually carried out under cooling or at ambient temperature.Process 4 The compound I4 or its salt can be prepared by reacting the compound CIV or its salt with a halogenating agent. Suitable salt of the compound IV may include an inorganic and organic base salt as exemplified for the compound CIa . Suitable examples of the halogenating agent may include chlorine, bromine, iodine, N chlorosuccinimide, N bromosuccinimide, N bromophthalimide and the like. .This reaction is usually carried out in a conventional solvent such as methanol, ethanol, chloroform, dioxane or any other solvent which does not adverselyinfluence the reaction. This reaction temperature is not critical and the reaction is usually carried out under cooling to warming.Process 5 The compound Ia or its salt can be prepared by removing the carboxy protective group of the compound 15a or its salt. 5 Suitable salt of the compound Ia may include an acid salt as exemplified for the compound Ia . In this elimination reaction, all conventional methods used in the elimination reaction of the protected carboxy, for example, hydrolysis, reduction, etc. can be applicable. When the protective group is an ester, it can be eliminated by hydrolysis, reduction or by using a Lewis acid which may be suitably selected in accordance with the kind of the carboxy protective group. The hydrolysis is preferably carried out in the presence of a base as exemplified in Process 1 or an inorganic or organic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, formic acid, trifluoroacetic acid, benzenesulfonic acid, p toluenesulfonic acid, etc. Suitable reduction may include the ones as exemplified in Process 2. Suitable Lewis acid may include aluminum trichloride and the like.This elimination reaction is usually carried out in a conventional solvent such as water, methanol, ethanol, acetic acid or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating.Process 6 The compound I7 or its salt can be prepared by subjecting the compound V or its salt to elimination reaction of the lower alkyl moiety at the lower alkoxy group. Suitable salt of the compound V may include an inorganic or organic base salt as exemplified for the compound la . This reaction is preferably carried out in the presence of a hydrohalogenic acid e.g. bydriodic acid, hydrobromic acid, etc.l, a Lewis acid e.g. alt un trichloride, etc. and the like. This reaction is usually carried out in a solvent such as water, acetic anhydride, acetic acid or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating.This invention includes, within its scope, the case that the protected carboxy is transformed into the free carboxy group during the reaction. The processes for the preparation of the starting compounds IIa ,.CIIb and IIc of this invention are explained in details as follows.Preparation A a Preparation of the compound rX The compound IX can be prepared by reacting the compound XI or its salt with the compound X . The suitable salts of the compound XI may include an acid salt e.g. hydrochloride, sulfate, etc. . This reaction is usually carried out in the presence of a conventional solvent such as acetone, methanol, tetrahydrofuran, chloroform, benzene or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating. Thus obtained compound CIX can be used in the next step without isolation. b Preparation of the compound VIII The compound VIII can be prepared by subjecting the compound IX wherein R4 is an acyl group, to deacylation reaction. This deacylation reaction can be carried out in a conventional manner such as hydrolysis or the like.This hydrolysis can be carried out in the similar manner to that illustrated in Process 5. C Preoaration of the compound CVII The compound VII . or its salt can be prepared by reacting the compound VIII with an oxidizing agent. Suitable examples of the, xidizing agent may include halogen e.g. chlorine, bromine, iodine, etc. , potassium ferricyanide and the like. This reaction is usually carried out in a solvent such as dichloromethane, chloroform, benzene or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating. d Preparation of the compound VI The compound VI can be prepared by reacting the compound VII or its salt with a diazotizing agent and than reacting the resultant compound with a cupric halide. Suitable salt of the compound VII may include the one as exemplified for the compound CXI . Suitable examples of the diazotizing agent may include the ones as exemplified in Process 3. The cupric halide may include cupric chloride, cupric bromide and the like. This reaction is usually carried out in a solvent such as acetonitrile, benzene, chloroform or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out under cooling or at ambient temperature. e Preparation of the compound IIa The compound IIa can be prepared by hydrolyzing the compound VI . This hydrolysis can be carried out in the similar manner to that illustrated in Process 5. Preparation B a Preparation of the compound CXI I The compound XII or its salt can be prepared by reacting the compound XIII or its salt with a metal polysulfide. Suitable salts of the compounds XII and XIII are the same as those exemplified for the compound XI . Suitable examples of the metal polysulfide may include alkali metal disulfde e.g. sodium disulfide, potassium disulfide, etc. and the like. This reaction is usually carried out in a con ventional solvent such as water, acetone, methanol, ethanol, aqueous methanol, aqueous acetone or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out under heating. b Preparation of the compound IIa The compound via can be prepared by reacting the compound CXI I or its salt with a metal monosulfide and then reacting the resultant compound with phosgene. In the first step, the compound CXII or its salt is reacted with,a metal monosulfide. Suitable examples of the metal monosulfide may include alkali metal monosulfide e.g. sodium monosulfide, potassium monosulfide, etc. and the like. This reaction is usually carried out in a conventional solvent such as water, methanol, ethanol, acetone, aqueous methanol, aqueous acetone or any other solvent which does not adversely influence the reaction. This reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating. Thus obtained compound can be used in the next step. without isolation. In the second step, phosgene is reacted with the said produced compound to give the compound IIa . This reaction is usually carried out in a conventional solvent such as water, acetone, methanol, ethanol, toluene or any other solvent which does not adversely influence the reaction. This reaction is preferably carried out in the presence of an inorganic or organic base as exemplified in Process l. This reaction temperature is not critical and the reaction is usually carried out at ambient tempera ture or under colling.preparation C a Preparation of the compound by IIb The compound IIb can be prepared by reacting the compound XIV with a nitrating agent. Suitable examples of the nitrating agent may include nitric acid, fuming nitric acid, a mixture of nitric acid and conc. sulfuric acid and the like. This reaction can be carried out in the presence or absence of a solvent such as water or any ether solvent which does not adversely influence the reaction. This reaction temperature is not critical and t react, ion is usually carried out under cooling or at ambient temperature. b Preparation of the compound IIc The compound IIc or its salt can be prepared by reducing the compound IIb . Suitable salts of the compound IIc are the same as those exemplified for the compound CXI . This reduction can be carried out in substantiaIly same manner to that illustrated in Process 2. The effective ingredient of the present pharmaceutical composition, i.e. the compound I or a pharmaceutical acceptable salt thereof is a highly potent inhibitor of aldose reductase. For illustrating this fact, some pharmacological data are shown in the following test.Test Inhibitory effect on rabbit lens aldose reductase I Test Compound 1 2 Oxo 5 chloro 6 phenoxy 3 benzothiazoline acetic acid. 2 2 Oxo 5 chloro 6 phenyl 3 benzothiazoline acetic acid 3 2 Oxo 6 phenoxy 3 benzothiazolineacetic acid 4 2 Oxo 6 20 chlorophenoxy 3 benzothiazoline acetic acid 5 2 Oxo 6 phenyl 7 chloro 3 benzothiazoline acetic acid 6 2 Oxo 5 chloro 6 cyclohexyl 3 benzothiazoline acetic acid 7 2 Oxo 5 chloro 6 phenyl 3 benzoxazolineacetic acid 8 2 Oxo 5 chloro 6 bromo 3 benzothiazolineacetic acid 9 2 Oxo 6 chloro 1 indolineacetic acid 10 2 Oxo 5 chloro 3 benzothiazolineacetic acid 11 2 Oxo 5 chloro 3 benzoxazolineacetic acid 12 2 Oxo 6 chloro 3 benzothiazolineacetic acid 13 2,3dioxo 6 chloro l indolineacetic acid 14 2 Oxo 5 methyl 6 phenyl 3 benzothiazolineacetic acid 15 2 Oxo 5,6 dichloro 3 benzothiazolineace5tic acid 16 2 Oxo 5 chloro 6 nitro 3 benzothiazolineacetic acid 17 2 Oxo 5 chloro 6 amino 3 benzothiazolineacetic acid CII Test Method The inhibitory effect 8 of the prescribed test compound at various concentrations was determined in substantially the same manner as described in theJournal of Biological Chemistry Vol. 240, page 877 196S , excepting that aldose reductase prepared from rabbit lens was used in place of that prepared from calf lens. 50 In hibitory concentration IC50 of the test compound was graphically calculated from the inhibitory effect as determined above. III Test Result The test results are shown in the following table. EMI22.1 tb Test SEP Compound SEP No. SEP IC50 SEP M SEP tb SEP 1 SEP 5.0 SEP x SEP 10 8 SEP tb SEP 2 SEP SEP 2.9 SEP x tb SEP 3 SEP 6.9 SEP x SEP 10 7 tb SEP 4 SEP 2.7 SEP x SEP 10 7 SEP tb SEP 5 SEP SEP 1.2 SEP x tb SEP 6 SEP 1.4 SEP x SEP 10 7 tb SEP 7 SEP 4.9 SEP x SEP 10 8 tb SEP 8 SEP 5.0 SEP x SEP 10 8 tb SEP 9 SEP 2.7 SEP x SEP 10 7 tb SEP 10 SEP 2.0 SEP x SEP 10 7 tb SEP 11 SEP 2.5 SEP x SEP 10 7 tb SEP 12 SEP SEP 4.1 SEP x SEP 10 7 tb SEP 13 SEP 3.0 SEP x SEP 10 7 tb SEP 14 SEP 3.3 SEP x SEP 10 8 tb SEP 15 SEP 3.8 SEP x SEP 10 8 tb SEP 16 SEP 1.2 SEP x SEP 10 7 SEP tb SEP 17 SEP 1.0 SEP x SEP 10 7 SEP tb For the preventiveness and treatment of diabetic complications in mammals, the compound I or its pharmaceutically acceptable salt can be administered in admixture with pharmaceutically acceptable carriers, i.e. in the form of a pharmaceuticai composition.The pharmaceutical composition of this invention can be formulated in the form of capsules, tablets, granules, powders, solutions, ophthalmic preparations e.g.eyedrop, ointment , etc. The pharmaceutically acceptable carriers may include various organic or inorganic carrier materials., which are conventionally used for pharmaceutical purpose, such as excipient te.g. sucrose, starch, mannit, sorbit, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, etc. , binding agent cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylen glycol, sucrose, starch, etc. , disintegrator e.g.starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropyl starc, sodium glycole starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc. , lubricant e.g. magnesium stearate, aerosil, talc, sodium laurylsulfate, etc. , flavoring agent e.g. citric acid, mentol, ammonium salt of grycyrlysine, glycine, orange powders, etc. , preservative sodium benzoate, sodium bisulfite, methylparabzn, propylparaben, etc. , stabilizer citric acid, sodium citrnte, acetic acid, etc. , suspending agent e.g. methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc. , dispersing agent e.g. polysolbate 80, emalgen 408 surface active agent , emasol surface active agent , etc. , aqueous diluting agent e.g. water , base wax e.g. cacao butter, polyethyleneglycol, witepsol, white petrolatum, etc. . A dosage of the object compounds is to be varied depending on various factors such as kind of diseases, weight and or age of a patient, and further the kind of administration route. Preferable dosage of compound I or its pharmaceutically acceptable salt is usually selected from within a range of about 0.1 100 mg kg day, but not limited thereto. The following preparations and examples are given for the purpose of illustrating this invention.Preparation 1 a To a solution of ammonium thiocyanate 30.2 g in anhydrous acetone 660 ml was added dropwise benzoyl chloride 47.6 g with stirring at 50 C. After refuting for 1.5 hours, the mixture was cooled to ambient temperature. To the mixture containing benzoyl isothiocyanate was added dropwise a solution of 2 phenoxyaniline 47.6 g in anhydrous acetone 300 ml . The reaction mixture was refluxed with stirring for 1.5 hours and then concentrated under reduced pressure to give crystals, which were washed twice with water and dried to give crystalline 1 2 phenoxyphenyl 3 benzoylthiourea. b Thus produced 1 92 phenoxyphenyl 3 benzoylthiourea was dissolved in a mixture of 10 aqueous sodium hydroxide 660 ml and methanol 530 ml at 50 C.The reaction mixture was stirred for 30 minutes at 50 C and then cooled with ice to give crystals, which were separated by filtration, washed with water and dried to give l 2 phenoxyphenyl thiourea mp 120 124 C.Preparation 2 The following compounds were prepared in substantially the same manner as those of Preparation 1 a and b , respectively. I a I 4 Phenoxyphenyl 3 benzoylthiourea mp 123 126 C b 1 C4 Phenoxyphenyl thiourea zp 180 184 C 2 a 1 3 Chloro 4 phenoxyphenyl 3 benzoylthiour ea b 1 3 Chloro 4 phenoxyphenyl thiourea mp 116 1200C 3 a 1 4 2 Chlorophenoxy phenyl 3 benzoylthiourea mp 116 119 C b 1 4 2 Chlorophenoxy phenyl thiourea mp 131 132 C 4 a 1 2 Chloro 4 biphenylyl 3 benzoylthiourea mp 123 1250C b 1 2 Chloro 4 biphenylyl thiourea mp 155 158 CPreParation 3 To a mixture of I 2 phenoxyphenyl thiourea 53.4 g in chloroform 100 ml was added dropwise a solution of bromine 35.0 g in chloroform 50 ml with stirring under ice cooling during 40 minutes.After refluxing for 1 hour and 40 minutes, the mixture was cooled to ambient temperature. To the resultant mixture was added water and then the mixture was alkalified with 5 sodium hydroxide aqueous solution. The chloroform layer was washed with water, dried over magnesium sulfate, concentrated under reduced pressure to give crystals, which were recrystallized twice from isopropyl alcohol to give 2 amino 4 phenoxybenzothiazole 25.8 g .mp 135 137 C. Prenarat on 4 The following compounds were prepared in substantially the same manner as, that of Preparation 3. 1 2 Amino 6 phenoxybenwothiaole mp 167 1690C 2 2 Amino 5 chloro 6 phenoxybenzothiazole 3 2 Amino 6 2 chlorophenoxy benzothiazole mp 161 1670C. Preparation 5 a To a solution of 1 C2 chloro 4 biphenylyl thiourea 5.3 g in chloroform 150 ml was added dropwise a solution of bromine 3.2 g in chloroform 10 ml with stirring at ambient temperature during 15 minutes. After the stirring was continued for 30 minutes at ambient temperature, the reaction mixture was refluxed for 5 hours and 15 minutes and then cooled to ambient temperature to give crystals, which were separated by filtration. To the crystals were added sodium bisulfite and aqueous sodium hydroxide.The mixture was extracted with ethyl acetate, washed with water, dried over magnesium sulfate and concentrated under reduced pressure to give a mixture of 2 amino 5 chloro 6 phenylbenzothiazole and 2 amino 6 phenyl 7 chlorobenzothiazole 4.1 g . b To a mixture of anhydrous cupric bromide C4.2 g in anhydrous acetonitrile 80 ml was added dropwise t butyl nitrite 2.6 g with stirring under icecooling. To the mixture was added dropwise a mixture of 2 amino 5 chloro 6 phenylbenzothiazole and 2 amino6 phenyl 7 chlorobenzothiazole 4.1 g with stirring under ice cooling during 10 minutes. After the stirring was continued under lce cooling for 1 hour and 40 minutes, the reaction mixture was concentrated under reduced pressure to give a residue, to which was added dil. hydrochloric acid. The mixture was extracted with chloroform.The organic layer was separated, washed with water, dried over magnesium sulfate and concentrated under reduced pressure to give an oily residue, which was chromatographed on silica gel using a mixture of benzene and hexane 1 2 as eluants to give the first Fraction A and the second Fraction B . The Fraction A gave crystalline 2 bromo 5 chloro 6 phenylbenzothiazole tl.0 g .mp 105 1080C NMR ppm DMSO d6 7.53 5H, s , 8.25 ClH, s , 8.28 , s .Further, the Fraction B gave crystalline 2 bromo6 phenyl 7 chlorobenzothiazole 1.5 g .mp. 105 109 CNMR p0pm DMSO d63 7.57 5H , s , 7.67 and 8.08 2H, ABq, J 9Hz .Preparation 6 To a mixture of anhydrous cupric bromide 22.1 g and anhydrous acetonitrile C320 ml was added dropwise t butyl nitrite 12.8 g with stirring under ice cooling. To the mixture was further added 2 amino 4 phenoxybenzothiazole 20.0 g with stirring under ice cooling during 25 minutes. After the stirring was continued for 1.5 hours under icecooling, acetonitrile was removed from the resultant mixture under reduced pressure to give a residue, which was dissolved in a small volume of dil. hydrochloric acid and extracted with ethyl acetate.The organic layer was washed with water, dried over magnesium sulfate, concentrated under reduced pressure to give oily residue, which was chromatographed on silica gel using a mixture of benzene and n hexane 1 1 as eluants. The fractions containing the object compound were collected and crystallized to give 2 bromo 4 phenoxybenzothiazole 99 g . mp 117 1210C. Preparation 7 The following compounds were prepared in substantially the same manner as that of Preparation 6. I 2 Bromo 6 phenoxybenzothiazole oil IR film 1605. 1590. 1560 cm Ú 2 2 Bromo 5 chloro 6 phenoxybenzothiazole mp 153 154 C 3 2 Bromo 6 2 chlorophenoxy benzothiazole oil IR film 1600, 1580, 1560 cm ÚPreparation 8 To a sodium ethoxide solution prepared with sodium metal 460 mg and anhydrous ethanol 50 ml was added 2 bromo 4 phenoxybenzothiazole 3.0 g .The mixture was refluxed with stirring 45 minutes.The solvent was removed under reduced pressure to give a residue, to which was added 10 hydrochloric acid 30 ml and acetone 50 ml . The resultant mixture was refluxed with stirring for 2 hours.The solvent was removed under reduced pressure to give a residue, which was recrystallized from a mixture of ethanol and n hexane to give crystalline 2 oxo 4 phenoxybenzothiazoline 2.0 g . mp 153 1550C Preparation 9 The following compounds were prepared in substantially the same manner as that of Preparation 8. 1 2 Oxo 6 phenoxybenzothiazoline mp 140 145 C 2 2 Oxo 5 chloro 6 phenoxybenzothiazoline mp 237 241 C 3 2 Oxo 6 2 chlorophenoxy benzothiazoline mp 132 133 C 4 2 Oxo 5 chloro 6 phenylbenzothiazoline mp 245 249 C 5 2 Oxo 6 phenyl 7 chlorobenzothiazoline mp 256 257 CPreparation 10 A mixture of sodium monosulfide.nonahydrate 14.7 g and sulfur 1.76 g in water 50 ml was stirred at 600C for an hour. The resultant sodium disulfide aqueous solution was added dropwise a solution of nitro 4 chlorodiphenyl ether 24.9 g in acetone t50 ml with stirring at 60 C during 30 minutes. The reaction mixture was refluxed with stirring for 45 minutes and then cooled to ambient temperature.Acetone was removed under reduced pre ssure to give crystals which were separated by filtration and washed with a small volume of acetone to give yellowish crystalline bis 2 nitro 4phenoxyphenyl disulfide 13.2 g . mp 118 1210C. Preparation 11 a To a solution of 1,4 dichlcrobenzene 294 g in anhydrous carbon disulfide 400 ml was added anhydrous aluminum chloride 16.0 g . To the mixture was added dropwise chlorocyclohexane 96 g with stirring at ambient temperature during 3 hours. After the stirring was continued for 3 hours at ambient temperature, the reaction mixture was allowed to stand overnight at ambient temperature. To the reaction mixture was added dil.hydrochloric acid with stirring. The organic layer was separated, washed with water, dried over magnesium sulfate, concentrated under reduced pressure and allowed to stand at ambient temperature for a while to give precipitates. The precipitates were removed by filtration. The filtrate was dis tilled under reduced pressure to give 1,4 dichloro 2 cyclohexylbenzene 47 . O Xg bp 138 C 5mmHg. b To a solution of l,4 dichloro 2 cyclohexylbenzene 12.0 g in conc.sulfuric acid 15 ml was added. dropwise a mixture of nitric acid d 1.42, 4 ml and conc.sulfuric acid 6 ml with stirring under ice cooling. After the stirring was continued for 10 minutes, ice water was added to the reaction mixture to give an oily residue, which was extracted with ether, washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The resul tant oily residue was distilled under reduced pressure to give 1,4 dichloro 2 cyclohexyl 5 nitrobenzene 10.0 g . bp 1700C 2mmHg. c Bis 2 nitro 4 chloro 5 cyclohexylphenyl disulfide was prepared from 1,4 dichloro 2 cyclohexyl 5 nittobenzene in substantially the same manner as that of Preparation 10. mp l83 184oC. Prepasation 12 A mixture of bis 2 nitro 4 phenoxyphenyl disulfide 13.2 g , sodium monosulfide nonahydrate 36.7 g in water was refluxed with stirring for 3 hours and then cooled to ambient temperature To the resultant mixture was added 10 sodium hydroxide aqueous solution 50 ml . Phosgene was passed through the reaction mixture with stirring under ice cooling until it was neutralized. The resultant mixture was acidified with hydrochloric acid, extracted with ethyl acetate, washed with water, dried over magnesium sulfate and concentrated under reduced pressure to give a residue, which was chromatographed on silica gel using benzene and a mixture of benzene and ethyl acetate 10 1 as eluants.The fractions containing object compound was concentrated under reduced pressure to give crystals, which were recrystallized from a mixture of benzene and n hexane to give crystalline 2 oxo 5 phenoxy benzothiazoline 4.0 g .mp 145 1500C. Prenaration 13 The following compound was prepared in substantially the same manner as that of Preparation lZ. 1 2 Oxo 5 chloro 6 cyclohexylbenzothiazoline mp 230 231 C.Preparation 14 To a mixture of 2 oxo 5 chlorobenzothiazoline 465 g in conc.sulfuric acid C500 ml was added dropwise a solution of nitric acid d l.42, 275 g in conc.sulfuric acid e500 ml with stirring at 100C during an hour. After the stirring was continued for an hour under ice cooling, to the resultant mixture was added ice water 10 liters to give crystals, which were separated by filtration, washed with water and dried to give 2 oxo 5 chloro 6 nitrobenzothiazoline 539 g .mp 235 C dec. .Preparation 15 The following compounds were prepared in substantially the same manner as that of Preparation 14. 1 2 Oxo 5 chloro 6 nitrobenzoxazoline mp 196 2030C 2 2 Oxo 5 nitro 6 chloroindoline crystals IR Nujol 1710, 1620, 1520, 1340, 1330 NMR tDMSO d6 ppm 3.55 2H, s , 6.95 1H, s , 7.93 lH, s 3 2 Oxo 5 methyl 6 nitrobenzothiazoline mp 2500C Preparation 16 To a mixture of ethanol 200 ml and water 40 ml were added ammonium chloride 2.2 g and iron metal 19.7 g . To the mixture was added 2 oxo 5nitro 6 chloroindoline 12.5 g at 60 C. After refluxing for 45 minutes, the reaction mixture was filtered under warm, condition. The filter cake was washed with ethanol. The combined filtrate and washings were evaporated to dryness under reduced pressure to give 2 oxo 5 amino 6 chloroindoline 10.0 g Example 1 A mixture of 2 oxo 4 phenoxybenzothiazoline 2.0 g , ethyl bromoacetate 1.7 g , potassium carbonate 1.4 g in acetone 30 ml was refluxed for an hour with stirring. After the resultant mixture was filtered, the filtrate was concentrated under reduced pressure to give a residue, which was recrystallized from a mixture of ethanol and n hexane to give crystalline ethyl 2 oxo 4 phenoxy.3 benzothiazolineacetate 2.0 g . mp 96 99 C.Example 2 The following compounds were prepared in substantially the same manner as that of Example 1. 1 Ethyl 2 oxo 5 phenoxy 3 benzothiazolineacetate mp 120 12Z0C. 2 Ethyl 2 oxo 6 phenoxy 3 benzothiazolinecetate mp 79 81 C 3 Ethyl 2 oxo S chloro 6 phenoxy 3 benzothiazo lineacetate mp 109 111 C 4 Ethyl 2 oxo 6 2 chlorophenoxy 3 benzothiazolineacetate oil t 5 Ethyl 2 oxo S chioro 6 phenyl 3 benzothiazolineacetate mp 130 1310C 6 Ethyl 2 oxo 6 phenyl 7 chloro 3 benzothizolineacetate mp 147 148 C 7 Methyl 2 oxo 5 chloro 6 cyclohexyl 3 benzothiazolineacetate mp 133 1340C Ethyl 2 oxo 5 methoxy 3 benzothiazolineacetate mp 83 840C 9 Ethyl 2 oxo 6 chloro 1 indolineacetate mp 135 1360C 10 Ethyl 2 oxo 5 chloro 6 nitro 3 benzothiazoline acetate mp 17Q 1710C 11 Ethyl 2 oxo 5 chloro 6 nitro 3 benzoxazoline acetate mp 126.5 128 C 12 Ethyl 2 f2 oxo 5 chloro 6 nitro 3 benzo thiazoline propionate mp ll2 1140C 13 Ethyl 2 oxo 5 methyl 6 nitro 3 benzo thiazolineacetate mp 159 160 CExample 3 A mixture of ethyl 2 oxo 5 chloro 6 amino 3benzothiazolineacetate 347.8 g and conc. hydrochloric acid 1040 ml was stirred for 30 minutes at ambient temperature. After the resultant mixture was cooled to 20C, 2 solution of sodium nitrite 88.3 g in water 120 ml was added dropwise thereto below 50C in the course of 40 minutes.The mixture was stirred for 20 minutes at OOC. To the resultant mixture was added benzene 5.2 2 in the course of 30 minutes.After the reaction mixture was stirred for an hour and 40 minutes under ice cooling, a solution of sodium acetate.3H2O 1.56 kg in water 3.6 L was added dropwise thereto under ice cooling in the course of an hour. The mixture was stirred overnight at ambient temperature. The organic layer was separated, washed with water and dried over anhydrous magnesium sulfate, concentrated under reduced pressure to give a residue,.which was recrystallized from ethanol to give ethyl 2 oxo 5 chloro 6 3 benzothiazolineacetate 311.5 g . mp 130 131 C.Example 4 The following compounds were prepared in substantially the same manner as that of Example 3. 1 Ethyl 2 oxo 5 chloro 6 phenyl 3 benzoxazoline acetate. mp 99 101 C 2 Ethyl 2 2 oxo 5 chloro 6 phenyl 3 benzothiazoline propionate, oil. IR film 1740, 1680 cm NMR DMSO d6 ppm 1.13 3H, t, J 7Hz , 1.58 3,R, d, J 6Hz , 4.13 2H, q, J 7Hz , 5.45 1H, q, J 6Hz , 7.2 7.7 7H, m 3 Ethyl 2 oxo 5 phenyl 6 chloro 1 indolineacetate mp 132 133 C 4 Ethyl 2 oxo 5 methyl 6 phenyl 3 benzothiazoline acetate. mp 138 141 CExample S To a solution of ethyl 2 oxo 5 chloro 6 phenoxy 3 benzothiazolineacetate 2.5 g in methanol 100 ml was added a solution of sodium hydroxide 360 mg in water 10 ml The reaction mixture was incubated for 15 minutes at 500C and then concentrated under reduced pressure to give a residue, which was acidified with dil.hydrochloric acid to give crystals, which were washed with water, dried and recrystallized from aqueous ethanol to give 2 oxo S chloro 6 phenoxy3 benzothiazolineacetic acid 2.2 g . mp 190 1940C. Example 6 To a solution of ethyl 2 oxo S chloro 6 phenyl 3 benzothiazolineacetate 269.6 g in ethanol 5.4 t was added dropwise a solution of sodium hydroxide 40.3 g in water 540 ml at 50 C in the course of 5 minutes. After stirring for 15 minutes at 50 C, the mixture was cooled to ambient temperature to give crystals, which were separated by filtration and washed with ethanol and acetone to give crystalline sodium salt of 2 oxo 5 chloro 6 phenyl 3 benzothiazolineacetic acid 217.3 g . The crystals were dissolved in water and acidified with dil.hydrochloric acid to give crude crystals, which were recrystallized from aqueous ethanol to give crystalline 2 oxo 5 chloro 6 phenyl 3 benzothiazolineacatic acid 131.9 g .mp 262 266 C. Example le 7 The following. compounds were prepared in substantially the same manner as those of Examples 5 and 6. 1 2 Oxo 4 phenoxy 3 benzothiazolineacetic acid mp 148 1510C. 2 2 Oxo 5 phenoxy 3 benzothiazolineacetic acid mp 179 1810C 3 2 Oxo 6 phenoxy 3 benzothiazolineacetic acid mp 150 152 C 4 2 Oxo 6 2 chlorophenoxy 3 benzothiazolineacetic acid mp 162 164 C 5 2 Oxo 6 phenyl 7 chloro 3 benzothiazolineacetic acid mp 254 257 C 6 2 Oxo 5 chloro 6 cyclohexyl 3 benzothiazoline acetic acid mp 222 226 C 7 2 2 Oxo 5 chloro 6 phenyl 3 benzothiazoline propionic acid mp 202 2030C 8 2 Oxo 5 methyl 6 phenyl 3 benzothiazolineacetic acid mp 245 250 C 9 2 Oxo 5 methoxy 3 benzothiazolineacetic acid mp 171 1740C 10 2 Oxa 6 chloro 1 indolineacetic acid mp 235 C dec.0 11 2 Oxo 5 chloro 6 amino 3 benzothiazolineacetic acid mp 246 2490C Example 8 To a solution of ethyl 2 oxo 5 chloro 6 phenyl 3 benzoxazolineacetate 1.5 g in acetic acid 10 ml was added conc.hydrochloric acid 5 ml . The reaction mixture was stirred at 60 C for 1.5 hou rs and then. cooled to ambient temperature. The resultant mixture was diluted with water to precipitate crystals, which were separated by filtration, washed with water, dried and then recrystallized from a mixture of chloroform and acetone to give 2 oxo 5 chloro 6 phenyl 3 benzoxazolineacetic acid. mp 200 2030C. Example 9 The following compounds were prepared in substantre tially the same manner as that of Example 8. 1 2 Oxo 5 phenyl 6 chloro 1 indolineacetic acid mp 260 2620C. 2 2 Oxo 5 chloro 6 nitro 3 benzothiazolineacetic acid mp 240 243 C dec. Example 10 To a mixture of 57 hydriodic acid 50 ml and acetic anhydride 15 ml was added a solution of ethyl 2 oxo 5 methoxy 5 benzothiazolineacetate 2.67 g in acetic acid 15 ml . The reaction mixture was refluxed with stirring for 1.5 hours and then cooled to ambient temperature. To the resultant mix ture were added ice water and a small volume of sodium bisulfite. The mixture was extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and concentrated under reduced pressure to give crystalline 2 oxo 5 hydroxy 3 benzothiazolineacetic acid 1.7 g . mp 217 221 C. Example 11 a To a solution of methyl 2 oxo 5 chloro 3 benzothiazolineacetate 10 g in dioxane 100 ml was added dropwise bromine 2 ml with stirring at 25 30 C during 40 minutes. After the stirring was continued at ambient temperature for 4 hours, precipitates in the resultant mixture were sepa rated by filtration, washed with dioxane and diethylether and dried to give crystalline methyl 2 oxo 5 chloro 6 bromo 5 benzothiazolinescetate 8.38 g . mp 209 2100C. b A mixture of methyl 2 oxo S. chloro 6 bromo 3 benzothiazolineacetate 2.0 g , methanol 250 ml and 10 sodium hydroxide aqueous solution 2.5 ml was refluxed with stirring for 1.5 hours and then cooled with ice water to give crystals, which were separated by filtrattoa. The filtrate was concentrated under reduced pressure to give crystals. The combined crystals were dissolved in water 80 ml under heating and then insoluble materials were removed by filtration.The filt rate was adjusted at pH 2 3 with 10 hydrochloric acid and cooled to give crystals, which were separated by filtration, washed with water and dried to give crystalline 2 oxo 5 chIoro 6 bromo 3 benzothiazolineacetic acid 1.5 g . mp 249 2520C. Example 12 The following compounds were prepared in substantially the same manner as those of Example 11 a and b , respectively. a Ethyl 2 oxo S ,6 dichloro 3 benzothiazolineacetate mp 147 1490C. b 2 Oxo 5,6 dichloro 3 benzothiazolineacetic acid mp 256 2580C. Example 13 To a mixture of ethanol 10 liters and water 1 liter were added ammonium chloride 25 g and iron metal 300 g . To the mixture was added ethyl 1 oxo 5 chloro 6 nitro 3 benzothiazolineacètate 434.6 g under mild reflux. After refluxing with stirring for 4 hours, the resultant mixture was filtered under warm condition. The filter cake was washed with ethanol. The combined filtrate and washings were concentrated under reduced pressure and cooled to ambient temperature to give crystals, which were separated by filtration to give crystalline ethyl 2 oxo 5 chloro 6 amins 3 benzothiazolineacetate 347.8 g . mp 154 1600C. Example 14 The following compounds were prepared in substantially the same manner as that of Example 13. 1 Ethyl 2 oxo 5 chloro 6 amino 3 benzoxazoline acetate. mp 137 141 C. 2 Ethyl 2 2 oxo 5 chloro 6 amino 3 benzo thiazoline propionate. mp 105 106 C. 3 Bthyl 2 oxo 5 methyl 6 amino 5 benzothiacoline acetate. mp 140 1420C . Example 15 To a mixture of 2 oxo 5 amino 6 chloroindoline 3.2 g , potassium carbonate 4.8 g and acetone 60 ml was added dropwise ethyl chloroacetate 3.2 g at ambient temperature. The reaction mixture was refluxed with stirring for 4 hours and then filtered under warm condition. The filter cake was washed with acetone. The combined filtrate and washings were concentrated under reduced pressure to give a residue, which was purified by a column chromato graphy on silica gel to give crystalline ethyl 2oxo 5 amino 6 chloro 1 indolineacetate 0.9 g0. IR Oujol 3440, 3330, 3220, 1750, 1690, 1590 cm NMR ppm CDCl3 6.64 lH, s , 6.55 1E, s , 4.34 2S, s , 4.19 2E, q, J 7Hz , 3,44 2H, 5 , 1,27 3H, t, J 7Hz Example 16 2 Oxo 5 chloro 6 phenyl 3 benzothiazcline acetic acid .500 g Starch 1987 Magnesium stearate 13 The above ingredients are blended and filled in hard gelatin capsules, in a conventional manner, to give 10,000 capsules, each of which contains 50 mg of an active ingredient, 2 oxo 5 chloro 6 phenyl 3benzothiazolineacetic acid. Example 17 2 Oxo 5 chloro 3 banzothiazolineacetic acid 250 g Starch 1980 Magnesi1nm stearate 20 The above ingredients are blended and filled in hard gelatin capsules, in a conventional manner, to give 10,000 capsules, each of which contains 25 mg of an active ingredient, 2 oso 5 chloro 3 benzothia zolineacetic acid.Example 18 2 Oxo 5 chloro 3 benzoxazolineacetic acid 20000 g Lactose 10400Starch 3600Ethyl cellulose 1800Magnesium stearate 200 The above ingredients are blended and compressed, in a conventional manner, into 10,000 tablets weighing 360 mg, each of which contains 200 mg of an active ingredient, 2 oro 5 chloro 3 benzoxazolineacetic acid.Thus obtained tablets are, when desired, coated with sugar coating, film coating or enteric coating.